Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-con
Authors
Andreas Pinter (ORCID: https://orcid.org/0000-0002-1330-1502)
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-con
Andreas Pinter, Yevgeniy Balagula, Brandon Becker, Virginia Hala et al.
Journal
JAAD International
Topics
Psoriasis: Treatment and Pathogenesis
article
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-con
Andreas Pinter, Yevgeniy Balagula, Brandon Becker, Virginia Hala, Ying-Ming Jou, Diamant Thaçi, Andrew Napoli, Christopher E.M. Griffiths, Matthias Hoffmann, Kristina Callis Duffin, Linda Stein Gold, Rachel Dyme, Mark Lebwohl, Andrew Blauvelt
article en
Abstract
No abstract available for this paper.
Publication Tag
JAAD InternationalVol. 25
Institutions
Goethe University Frankfurt (DE), Henry Ford Health System (US), King's College London (GB), University of Utah (US), Manchester Academic Health Science Centre (GB), University of Manchester (GB), Bristol-Myers Squibb (United States) (US), Maryland Department of Natural Resources (US), Marien Hospital Witten (DE), University Hospital Frankfurt (DE), King's College Hospital (GB), NIHR Manchester Biomedical Research Centre (GB), University of Lübeck (DE), Icahn School of Medicine at Mount Sinai (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-con — Andreas Pinter, Yevgeniy Balagula, et al. · JAAD International (2025) | TGRS Research Map | TGRS